This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

Also called NCT03448406

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 315 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03448406
  • EudraCT 2017-004072-59
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Germany, Greece, Italy, Norway, Poland, Portugal, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03448406. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2019-10-04 (actual). Results posted on 2020-12-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
Condition
Heart Failure
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03448406
Content hash
9f88c24c63bb09b0c04537eebe47dec104ca3f96a8f55239f08e5d9cfe340712